Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
The Associated Press; 50 Rockefeller Plaza, New York, NY 10020 - Thursday, September 4, 1997; 5:03 p.m. EDT
Daniel Q. Haney, AP Medical Editor
The idea is to fight infection with infection. The newly created viruses target only cells that have already been captured by HIV.
The approach works well in the test tube but has not been tried yet in people or even in animals. Even though no one knows whether it will eventually help control AIDS, experts say the idea is noteworthy for its novelty alone.
"It's absolutely amazing that you can make a virus that will specifically target HIV-infected cells," said Dr. Ronald Desrosiers of the New England Regional Primate Center, who plans to begin testing one of the viruses soon on monkeys.
One version of the virus, created by Dr. John K. Rose and his research team at Yale Medical School, is a genetically altered form of vesicular stomatitis virus, or VSV, a bug that ordinarily infects livestock. Another is based on the rabies virus and was created by a team led by Dr. Karl-Klaus Conzelmann of the Federal Research Center for Virus Diseases of Animals in Tubingen, Germany.
"It's a completely new approach to limiting viral infection," Rose said. "This is the first virus that's an anti-virus."
Reports on both experiments are being published in Friday's issue of the journal Cell. An accompanying commentary by Dr. Garry P. Nolan of Stanford University called the work "highly significant" and "a leap forward."
If it works as its developers hope, the technique will stop the AIDS virus cold by employing a sort of mirror image of HIV's own sly tricks for worming its way into cells.
Each individual bit of HIV is a ball of genetic material wrapped in a protein known as gp120. This substance has a powerful chemical attraction to two other proteins called CD4 and fusin. Some types of blood cells carry CD4 and fusin on their surfaces. And the AIDS virus uses its gp120 as a magnet to attach itself to these cells.
Once gp120 latches onto these two proteins, HIV opens the cell and squirts its genetic blueprint inside. This information is then stitched into the cells' own genes, turning them into virus-building factories. Along the way, the infected cells produce more gp120 and carry it on their surfaces.
In the new experiments, the scientists built versions of rabies and VSV that are missing their original outer coats. Instead, their surfaces are made of CD4 and fusin.
Reversing the process of HIV infection, this CD4 and fusin is attracted to the gp120 on the surface of the AIDS-infected cells. The genetically engineered virus enters and takes charge. After a few hours, the cell dies, never producing HIV.
The experimental rabies virus cannot reproduce. However, Yale's bullet-shaped VSV can actually command the cell to make new versions of itself before killing it. These new bits of VSV can then spread to other HIV-infected cells, essentially becoming a self-manufacturing AIDS drug.
Dr. Edward A. Berger of the National Institute of Allergy and Infectious Diseases, who discovered fusin last year, called the approach "interesting and clever."
"This is a selective way of delivering something to the HIV-infected cell, in this case a virus that will kill the cell," he said.
In the test tube, the reproducing VSV was able to reduce levels of HIV to almost zero for three months. This means the treatment is unlikely to wipe out HIV, even if it works, but it might be used with other medicines to keep HIV infections from progressing to AIDS.
The newly created viruses are designed to attack HIV-infected cells and nothing else. However, the safety of the new approach will be one of the first questions to be answered.
Other unknowns involve whether the immune system will attack cells that are infected with the genetically engineered viruses.
Copyright 1997/The Associated Press. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, The Associated Press, 50 Rockefeller Plaza, New York, NY 10020.
970904
AP970902
Copyright © 1997 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .